Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Ebumab is a biotechnology research company utilizing AMT technology in combination with the body’s own immune system to fight cancer.
Sevenless Therapeutics focus on manufacturing of pharmaceuticals.
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection.
Paragit Solutions develops systems for improving care and diagnosis of movement disorders.
Probmet is a precision oncology therapeutics company developing treatments for cancer.
Ampa Medical provides healthcare services for people living with an ostomy.
Pephexia Therapeutics is a biotechnology company working with the discovery.
Embark Biotech is a biotech company identifying cell surface receptors regulating fat tissue calorie-burning and glucose and lipid uptake.
Cirqle Biomedical develops innovative contraceptives utilizing mucus engineering technology.
Ciana Therapeutics is a clinical development-stage company developing novel therapies focusing on diabetic retinopathy.
Lophora develops new rapid-acting drugs for central nervous system diseases including treatment-resistant depression.
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
RetiPharma is a Danish Biotech company
BioInnovation Institute has invested in 157 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
BioInnovation Institute's top investment sectors include Medical, Biotechnology, Health Care, Therapeutics, Medical Device. The firm invests across 12 different industry categories.
Among tracked funding rounds, Synklino received $32.0M in a Series A round. BioInnovation Institute's total known invested capital is $402.9M.
BioInnovation Institute's average investment size is $3.6M across its portfolio of 157 companies.
Recent BioInnovation Institute portfolio additions include Ebumab, Sevenless Therapeutics, Synklino, Paragit Solutions, Probmet. These companies were founded in 2020 or later.